Table 3.
Analysis of variables associated with confirmed prostate-specific antigen response
| Characteristics | Patient (n) | Confirmed PSA response, n (%) | P |
|---|---|---|---|
| All patients | 146 | 71 (48.6) | |
| Age (year) | |||
| <70 | 45 | 17 (37.8) | 0.106 |
| ≥70 | 101 | 54 (53.5) | |
| Hemoglobin (g l−1) | |||
| <120 | 67 | 29 (43.3) | 0.249 |
| ≥120 | 79 | 42 (53.2) | |
| ALP (U l−1) | |||
| <160 | 83 | 47 (56.6) | 0.031 |
| ≥160 | 63 | 24 (38.1) | |
| LDH (U l−1) | |||
| <250 | 75 | 44 (58.7) | 0.014 |
| ≥250 | 71 | 27 (38.0) | |
| ALB (g l−1) | |||
| <35 | 29 | 16 (55.2) | 0.534 |
| ≥35 | 117 | 55 (47.0) | |
| ECOG performance status | |||
| 0–1 | 131 | 67 (51.1) | 0.102 |
| ≥2 | 15 | 4 (26.7) | |
| Gleason score of primary lesion | |||
| 5–7 | 39 | 28 (71.8) | 0.001 |
| 8–10 | 107 | 43 (40.2) | |
| Duration of previous hormonal therapy (month) | |||
| <16.0 | 73 | 32 (43.8) | 0.320 |
| ≥16.0 | 73 | 39 (53.4) | |
| Extent of disease | |||
| 0–5 metastatic sites | 91 | 58 (63.7) | <0.001 |
| >5 metastatic sites | 55 | 13 (23.6) | |
| Visceral metastases | |||
| Yes | 15 | 4 (26.7) | 0.102 |
| No | 131 | 67 (51.1) | |
| Previous docetaxel chemotherapy | |||
| Yes | 43 | 15 (34.9) | 0.047 |
| No | 103 | 56 (54.4) |
ALP: alkaline phosphatase; LDH: lactate dehydrogenase; ALB: albumin; ECOG: Eastern Cooperative Oncology Group; PSA: prostate-specific antigen